Cargando…
Evaluating the safety and potential activity of URO‐902 (hMaxi‐K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non‐neurogenic) overactive bladder syndrome and detrusor overactivity from two double‐blind, imbalanced, placebo‐controlled randomized phase 1 trials
AIMS: Two phase 1 trials were performed in healthy women with the overactive bladder (OAB) syndrome and urodynamically demonstrated detrusor overactivity (DO), with the aim to demonstrate the safety and potential efficacy of URO‐902, which comprises a gene therapy plasmid vector expressing the human...
Autores principales: | Rovner, Eric, Chai, Toby C., Jacobs, Sharon, Christ, George, Andersson, Karl‐Erik, Efros, Mitchell, Nitti, Victor, Davies, Kelvin, McCullough, Andrew R., Melman, Arnold |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028015/ https://www.ncbi.nlm.nih.gov/pubmed/31945197 http://dx.doi.org/10.1002/nau.24272 |
Ejemplares similares
-
Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011) -
Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023) -
Intravesical Liposome and Antisense Treatment for Detrusor Overactivity and Interstitial Cystitis/Painful Bladder Syndrome
por: Tyagi, Pradeep, et al.
Publicado: (2014) -
Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020) -
Coexisting overactive–underactive bladder and detrusor overactivity–underactivity in pelvic organ prolapse
por: Frigerio, Matteo, et al.
Publicado: (2022)